Search results
Results From The WOW.Com Content Network
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs ... side effects of ... anthrax (prophylaxis and treatment) ...
In March 2016, obiltoxaximab was approved by the U.S. Food and Drug Administration (FDA) for the treatment and prophylaxis of inhalational anthrax. [10]In September 2020, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization under exceptional circumstances for ...
Skin lesion from anthrax Anthrax skin lesion on the neck Anthrax skin lesion on the face Cutaneous anthrax, also known as hide-porter's disease, is when anthrax occurs on the skin. It is the most common (>90% of cases) and least dangerous form (low mortality with treatment, 23.7% mortality without).
Anthrax vaccine adsorbed is classified as a subunit vaccine that is cell-free and containing no whole or live anthrax bacteria. [7] The antigen (immunologically active) portions are produced from culture filtrates of a toxigenic, but avirulent, nonencapsulated mutant — known as V770-NP1-R — of the B. anthracis Vollum strain. [8]
Raxibacumab [2] is a human monoclonal antibody intended for the prophylaxis and treatment of inhaled anthrax.Its efficacy has been proven in rabbits and monkeys. [3] In December 2012 raxibacumab was approved in the United States for the treatment of inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, and for prophylaxis of inhalational anthrax ...
Drug interactions with anthracyclines can be complex and might be due to the effect, side effects, or metabolism of the anthracycline. Drugs which inhibit Cytochrome P450 or other oxidases may reduce clearance of anthracyclines, prolonging their circulating half-life which can increase cardiotoxicity and other side effects. [ 57 ]
Type A: augmented pharmacological effects, which are dose-dependent and predictable [5]; Type A reactions, which constitute approximately 80% of adverse drug reactions, are usually a consequence of the drug's primary pharmacological effect (e.g., bleeding when using the anticoagulant warfarin) or a low therapeutic index of the drug (e.g., nausea from digoxin), and they are therefore predictable.
For premium support please call: 800-290-4726 more ways to reach us